iRadimed (NASDAQ:IRMD) Sets New 52-Week High – Time to Buy?

iRadimed Corporation (NASDAQ:IRMD) reached a new 52-week high during trading on Wednesday . The company traded as high as $101.00 and last traded at $100.3550, with a volume of 19622 shares traded. The stock had previously closed at $99.25.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IRMD. Zacks Research raised shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.33.

iRadimed Stock Up 2.9%

The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 61.93 and a beta of 1.09. The stock has a 50 day simple moving average of $93.37 and a 200 day simple moving average of $77.62.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. The firm had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were given a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Insider Buying and Selling

In other iRadimed news, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer owned 7,362 shares of the company’s stock, valued at $716,248.98. The trade was a 67.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $97.45, for a total value of $487,250.00. Following the transaction, the chief executive officer owned 2,272,500 shares of the company’s stock, valued at $221,455,125. This trade represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 60,000 shares of company stock valued at $5,451,200 over the last three months. Corporate insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares during the period. Quarry LP bought a new stake in iRadimed during the third quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its position in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. State of Alaska Department of Revenue bought a new position in iRadimed during the 3rd quarter valued at $47,000. Finally, Spire Wealth Management acquired a new position in shares of iRadimed during the 2nd quarter valued at $60,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.